Pediatric Annals

PRODUCT REPORT

Abstract

The Product Report was designed to provide pediatricians with up-to-date information ©n new medical equipmenr. office accessories, etc. Listings are made up from unsolicited press releases from the manufacturer. They are neither advertisements nor endorsements.

Rehydralyte"

Pedialyte RS® Oral Electrolyte Rehydration Solution has been renamed. It is now called Rehydralyte Oral Electrolyte Rehydration Solution. Pedialyte® Oral Electrolyte Maintenance Solution will continue to be known by its current name.

Rehydralyte is formulated to replace fluids and electrolytes lost by infants and children who are mildly to moderately dehydrated from acute diarrhea. Rehydralyte is a safe and effective alternative to intravenous therapy for most patients.

Manufactured by Ross Laboratories, Columbus, Ohio, Rehydralyte meets the recommendations of the American Academy of Pediatrics Committee on Nutrition for oral rehydration solutions for sodium, potassium, and carbohydrate.

Rehydralyte is packaged in convenient 8-oz glass nursing bottles and is ready to use, which avoids mixing or dilution errors. Rehydralyte is available in hospitals and pharmacies.

For continued fluid and electrolyte maintenance following rehydration, a separate oral electrolyte maintenance solution such as Pedialyte Oral Electrolyte Maintenance Solution may be used,

For information, contact Patrice Kelly Ross Laboratories, 625 Cleveland Avenue, Columbus, OH 43216; telephone (614J 227-3333.

Single Dose Vaccine

b-Capsa I single dose vial was approved for marketing by the FDA on March 27, 1987. b-Capsa I. the first available vaccine against Haemophilus influenza type b diseases in young children, is distributed by the Mead Johnson Nutritional Division of Bristol-Myers US Pharmaceutical and Nutritional Group.

"By introducing b-Capsa I in a single dose vial, we are offering an expansion in our product sizes to meet the specific needs of various practices," said Howard Willson, President of Mead Johnson Nutritional Division. "The single dose is often preferred by physicians with smaller pediatric practices."

b-Capsa I was used in the first large scale, multicenter US study on Hib vaccines. Henry Shinefield, MD, director of the study has concluded that "b-Capsa I Haemophilus influenza type b vaccine is safe and not associated with any serious long-term sequelae." Moreover, Dr. Shinefield reports, "side effects of vaccination with the vaccine are limited to mild local reactions and rare episodes of bronchospasm." The study involved 87,541 children between the ages of 2 and 5 years at 22 Northern California Kaiser Permanente Medical Group Centers. Dr. Shinefield is Chief of Pediatrics at Kaiser Permanente Medical Groups in San Francisco, and Professor of Pediatrics at the University of California, San Francisco.

A study of the vaccine's efficacy is being conducted in five phases. Dr. Shinefield reports that to date intermediate review seems to indicate that efficacy is consistent with package insert.…

The Product Report was designed to provide pediatricians with up-to-date information ©n new medical equipmenr. office accessories, etc. Listings are made up from unsolicited press releases from the manufacturer. They are neither advertisements nor endorsements.

New Alr-Stlrrup

An early return to function is now possible for pediatric patients and small adults recovering from ankle injuries through the use of the new "Small" Air-Stirrup Ankle Brace.

This modified 8.8" version of Aircast's original Ankle Brace is specially designed for people under S' 2" in height. It incorporates rigid premolded sides for protection and support, and approximates the ankle contours of a child or small adult with strategically placed cups formed to accommodate the malleoli. Preinflated aircells line the interior to provide patient comfort and squeeze away swelling through compression during weight-bearing activities.

Aircast's patented Air-Stirrup permits normal flexion for mobility while resisting inversion and eversión. This flexibility permits the early return to function, promoting the healing of injured ankles as documented by recent studies.

Ai rea st, Inc., in Summit, New Jersey, pioneered the development of pneumatic braces for the ankle, lower leg, knee and elbow.

Juvenile Diabetes Film

Milner-Fenwick Inc. announces the revision of one of its most popular diabetes tapes, "Our Friend EDI." This program on juvenile diabetes was originally developed with Eli Lilly Co. under the direction of the now retired medical director, S.O. Waife, MD. It has been revised to include all new information about proper blood glucose monitoring and diet.

The program addresses the uncertainty and fear many young patients and their families have about diabetes. EDI (property named to stand for the key elements of diabetes management - exercise, diet, and insulin) is a cartoon character. Superimposed over live scenes of a young boy recently diagnosed as having diabetes, EDI helps children and parents alike learn what diabetes is and how to manage it, and dispels the fears and myths surrounding the disease.

Diabetes educators and other health care professionals will find this tape especially useful because the entertaining format helps keep the young patient's attention and allows the child to understand the disease and its management. Most importantly EDI reassures children watching the tape that they can live a relatively normal life.

"Our Friend EDI" is part of a series of tapes on diabetes. Other topics include "Exercise for the Diabetic," "Blood Glucose Monitoring," and "Minimizing the Long Term Complications of Diabetes. "These programs are available in VHS, Beta, and V* inch U-matic video formats for single monitor viewing or with broadcast rights for CCTV Tapes may be previewed. Ib order, call toll free 1-800-638-8652 between 9H)O am and 630 PM ET, or write Milner-Fenwick, Inc., 2125 Greensprlng Drive, Tlmonium, MD 21093.

Detect-A-Strep® Announces Four New Kits

Antibodies Incorporated of Davis, California, announced a major packaging change for its popular line of Detect A Strep® kits. According to Steve Anderson, Al. Marketing Director, the company responded to the needs of diagnostic clinics and physicians' offices by increasing the amount of product in each kit. The company is making available a 35- and a 75determination test kit. In all, the company offers Detect A Strep® in four distinct options to meet the needs of individual offices or clinics. Each kit is packaged in a complete work station and each size is available with or without swabs and tubes.

Detect A Strep® was introduced nearly 2 years ago as the first rapid agglutination system for the detection of group A Streptococcus featuring a 7-minute protocol, 97.4% overall accuracy, and a simple room-temperature storage capability.

Detect A Strep® is available through distributors nationwide or by ordering direct from the company. For more information contact Antibodies Incorporated, P.O. Box 1560, Davis, CA 95617

Rehydralyte"

Pedialyte RS® Oral Electrolyte Rehydration Solution has been renamed. It is now called Rehydralyte Oral Electrolyte Rehydration Solution. Pedialyte® Oral Electrolyte Maintenance Solution will continue to be known by its current name.

Rehydralyte is formulated to replace fluids and electrolytes lost by infants and children who are mildly to moderately dehydrated from acute diarrhea. Rehydralyte is a safe and effective alternative to intravenous therapy for most patients.

Manufactured by Ross Laboratories, Columbus, Ohio, Rehydralyte meets the recommendations of the American Academy of Pediatrics Committee on Nutrition for oral rehydration solutions for sodium, potassium, and carbohydrate.

Rehydralyte is packaged in convenient 8-oz glass nursing bottles and is ready to use, which avoids mixing or dilution errors. Rehydralyte is available in hospitals and pharmacies.

For continued fluid and electrolyte maintenance following rehydration, a separate oral electrolyte maintenance solution such as Pedialyte Oral Electrolyte Maintenance Solution may be used,

For information, contact Patrice Kelly Ross Laboratories, 625 Cleveland Avenue, Columbus, OH 43216; telephone (614J 227-3333.

Single Dose Vaccine

b-Capsa I single dose vial was approved for marketing by the FDA on March 27, 1987. b-Capsa I. the first available vaccine against Haemophilus influenza type b diseases in young children, is distributed by the Mead Johnson Nutritional Division of Bristol-Myers US Pharmaceutical and Nutritional Group.

"By introducing b-Capsa I in a single dose vial, we are offering an expansion in our product sizes to meet the specific needs of various practices," said Howard Willson, President of Mead Johnson Nutritional Division. "The single dose is often preferred by physicians with smaller pediatric practices."

b-Capsa I was used in the first large scale, multicenter US study on Hib vaccines. Henry Shinefield, MD, director of the study has concluded that "b-Capsa I Haemophilus influenza type b vaccine is safe and not associated with any serious long-term sequelae." Moreover, Dr. Shinefield reports, "side effects of vaccination with the vaccine are limited to mild local reactions and rare episodes of bronchospasm." The study involved 87,541 children between the ages of 2 and 5 years at 22 Northern California Kaiser Permanente Medical Group Centers. Dr. Shinefield is Chief of Pediatrics at Kaiser Permanente Medical Groups in San Francisco, and Professor of Pediatrics at the University of California, San Francisco.

A study of the vaccine's efficacy is being conducted in five phases. Dr. Shinefield reports that to date intermediate review seems to indicate that efficacy is consistent with package insert.

10.3928/0090-4481-19870901-11

Sign up to receive

Journal E-contents